Sunday 18 October 2026
Export OBIO’s income statement to Excel — free account
Orchestra BioMed Holdings, Inc.
OBIO Healthcare Biotechnology
Orchestra BioMed Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.5 million, up 1,169.2% from fiscal 2024. In the quarter to June 2026, revenue fell 89.5%, EPS grew 24.0%, free cash flow fell 25.9% and total debt rose 142.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.45
0.29
−5.05%
Follow OBIO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 2 | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Altman Z-Score |
(2.72) | (5.57) | 2.27 | (1.10) | — | — | — | — |
P/S ratio |
5.92 | 55.83 | 105.69 | 42.60 | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(7.20) | (13.57) | (4.16) | (3.29) | — | — | — | — |
Beneish M-Score |
7.00 | (3.80) | (2.68) | — | — | — | — | — |
P/Operating CF |
(87.29) | (10.88) | (26.58) | (17.21) | — | — | — | — |
P/B ratio |
3.70 | 4.47 | 4.29 | 2.86 | — | — | — | — |
Price to Tangible BV |
3.70 | 4.47 | 4.29 | 2.86 | — | — | — | — |
EV/Sales |
3.16 | 35.92 | 74.36 | 21.57 | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
EV/Operating CF |
(2.16) | (1.87) | (4.45) | (2.60) | — | — | — | — |
EV/FCF |
(2.14) | (1.86) | (4.44) | (2.55) | — | — | — | — |
Quick Ratio |
6.37 | 4.13 | 7.82 | 4.52 | 10.60 | 17.03 | — | — |
Current Ratio |
6.45 | 4.27 | 7.95 | 4.56 | 10.88 | 18.06 | — | — |
Net Debt/EBITDA |
1.80 | 0.82 | 1.71 | 2.30 | 4.44 | 11.26 | — | — |
Debt/Assets |
12.42% | 18.76% | 0.00% | 9.93% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.27 | 0.43 | 0.00 | 0.18 | 0.00 | 0.00 | — | — |
Asset Turnover |
0.35 | 0.03 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.92 | 0.83 | 0.94 | 0.87 | 0.72 | 1.49 | — | — |
Capex/Depreciation |
(0.90) | (0.85) | (0.20) | (1.54) | — | — | — | — |
| (122.40%) | (120.84%) | (81.47%) | (138.33%) | 10.09% | 4.62% | — | — | |
| (55.44%) | (71.21%) | (51.49%) | (26.11%) | (0.23%) | (0.21%) | 0.00% | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Return on Tangible Assets |
(57.01%) | (112.28%) | (62.03%) | (49.71%) | (23.16%) | (8.55%) | — | — |
Average Days of Receivables |
1.04 | 12.73 | 13.09 | 9.92 | — | — | — | — |
Research and Development Expense of Revenue |
173.78% | 1,622.59% | 1,225.43% | 621.14% | — | — | — | — |
Selling, General and Administrative Expense of Revenue |
80.38% | 907.16% | 733.99% | 397.23% | 0.00% | 0.00% | — | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
35.77% | 402.39% | 276.27% | 96.60% | — | — | — | — |
Graham Net Nets |
0.24 | 0.18 | 0.21 | 0.28 | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Earnings Yield |
(27.23%) | (41.75%) | (17.08%) | (22.33%) | — | — | — | — |
Free Cash Flow Yield |
(24.96%) | (34.52%) | (15.84%) | (19.86%) | — | — | — | — |
Revenue per Share |
0.70 | 0.07 | 0.08 | 0.24 | 0.00 | 0.00 | — | — |
Operating CF per Share |
(1.03) | (1.37) | (1.39) | (1.95) | (0.01) | (0.02) | — | — |
Capex per Share |
(0.01) | (0.01) | 0.00 | (0.04) | 0.00 | 0.00 | — | — |
Free Cash Flow per Share |
(1.04) | (1.38) | (1.39) | (1.99) | (0.01) | (0.02) | — | — |
Cash per Share |
2.23 | 1.81 | 2.64 | 5.59 | 0.09 | 0.13 | — | — |
Shareholders Equity per Share |
1.12 | 0.90 | 2.05 | 3.50 | (0.19) | (0.23) | — | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Book value per Share |
1.12 | 0.90 | 2.05 | 3.50 | (0.19) | (0.23) | — | — |
Free Cash Flow |
(49.45) | (50.85) | (46.20) | (29.88) | (0.27) | (0.26) | — | — |
Working Capital |
91.18 | 52.96 | 77.91 | 66.12 | 1.64 | 2.03 | — | — |
Capital Expenditures |
(0.49) | (0.29) | (0.08) | (0.59) | — | — | — | — |
Net Current Asset Value |
46.62 | 25.96 | 61.95 | 41.65 | (163.96) | (163.57) | — | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Capex to Sales |
0.01 | 0.11 | 0.03 | 0.17 | — | — | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.32 | 0.24 | 0.31 | 0.26 | — | — | — | — |
Cash ROIC |
(28.36%) | (44.58%) | (29.69%) | (20.49%) | 12.45% | 16.83% | — | — |
Accounts Receivable Turnover |
358.10 | 27.62 | 28.31 | 0.00 | — | — | — | — |
Accounts Payable Turnover |
0.03 | 0.05 | 0.05 | 0.11 | 0.00 | 0.00 | — | — |
Inventory Turnover |
0.79 | 1.28 | 0.88 | 0.00 | — | — | — | — |
Average Days of Payables |
11,708.82 | 9,185.83 | 5,690.86 | 6,864.08 | 0.00 | 0.00 | — | — |
Days of Inventory on Hand |
595.53 | 309.53 | 286.51 | 477.44 | — | — | — | — |
Average Receivables |
0.09 | 0.10 | 0.10 | — | — | — | — | — |
Average Payables |
5.61 | 4.02 | 3.43 | 1.98 | 0.01 | 0.01 | — | — |
Average Inventory |
0.24 | 0.16 | 0.21 | — | — | — | — | — |
Average Assets |
95.52 | 85.69 | 95.39 | 128.70 | 161.99 | 81.08 | 0.00 | — |
Average Common Equity |
43.26 | 50.50 | 60.29 | 24.30 | (3.75) | (3.75) | — | — |
Columns are period end dates